Autonomic Nervous System Pharmacology

Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application

Volumn , Issue , 2013, Pages 218-234

  Ebert, Thomas J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880245109     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1679-5.00013-2     Document Type: Chapter

References (87)

1. Brienza N, Malcangi V, Dalfino L, et al. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Crit Care Med 2006, 34:707-714. In a prospective, multicenter RCT of critically ill patients in the ICU with early renal dysfunction, fenoldopam improved renal function compared with renal dose dopamine. (Ref. 24).
2. Flynn RA, Glynn DA, Kennedy MP Anticholinergic treatment in airways diseases. Adv Ther 2009, 26:908-919. An excellent review of the history, pharmacokinetics and effectiveness of anticholinergic treatment for both chronic obstructive pulmonary disease and asthma. (Ref. 78).
3. Friedrich JO, Adhikari N, Herridge MS, Beyene J Metaanalysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005, 142:510-524. A meta-analysis of 61 trials to evaluate the renal effects of low-dose dopamine. Compared with placebo, dopamine did not significantly alter mortality, the need for renal replacement therapy, or creatinine clearance. (Ref. 20).
4. Landoni G, Biondi-Zoccai GG, Marino G, et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2008, 22:27-33. In a meta-analysis of 13 RCT in patients undergoing cardiovascular surgery, the use of fenoldopam reduced the requirement for renal replacement therapy and reduced overall mortality compared to conventional therapy. (Ref. 25).
5. Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008, 371:1839-1847. POISE Study Group, In a large (>8300 patients) prospective RCT, patients at risk for atherosclerotic disease undergoing non-cardiac surgery received either extended-release metoprolol or placebo beginning 2 to 4 days before surgery and continued to 30 days postsurgery. The β-blockade group had fewer myocardial infarctions but more strokes and a higher death rate. (Ref. 65).
6. Raab H, Lindner KH, Wenzel V Preventing cardiac arrest during hemorrhagic shock with vasopressin. Crit Care Med 2008, 36(Suppl):S474-S480. One-third of traumatic injury deaths are due to uncontrolled hemorrhagic shock. Vasopressin amplifies the neuroendocrine stress response to hemorrhage via activation of receptors in vascular beds other than coronary, cerebral, and pulmonary. The authors review the theory and actions of vasopressin in this setting. (Ref. 56).
7. Riker RR, Shehabi Y, Bokesch PM, et al. SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009, 301:489-499. A prospective, double-blind RCT comparing the safety and efficacy of dexmedetomidine to midazolam for sedation in critically ill patients on mechanical ventilation. Dexmedetomidine achieved equivalent time in the targeted sedation range compared to midazolam and resulted in less delirium, tachycardia, and hypertension. There was more bradycardia in the dexmedetomidine treatment group. (Ref. 41).
8. Wallace AW, Au S, Cason BA Perioperative beta-blockade: atenolol is associated with reduced mortality when compared to metoprolol. Anesthesiology 2011, 114:824-836. In a large retrospective analysis of 30-day and 1-year mortality following major inpatient surgery, perioperative β-blockade using atenolol was associated with reduced short- and long-term postoperative mortality compared with metoprolol. (Ref. 70).
9. Chen KK, Schmidt GF The action of ephedrine, the active principle of the Chinese drug ma huang. J Pharmacol Exp Ther 1924, 24:339.
10. Nagai T Ephedrin. Pharm Zeit 1887, 32:700.
11. Ahlquist RP A study of the adrenotropic receptors. Am J Physiol 1948, 153:586-600.
12. Wikberg JE Adrenergic receptors: classification, ligand binding and molecular properties. Acta Med Scand Suppl 1982, 665:19-36.
13. Minneman KP, Molinoff PB Classification and quantitation of beta-adrenergic receptor subtypes. Biochem Pharmacol 1980, 29:1317-1323.
14. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967, 214:597-598.
15. Docherty JR Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur J Pharmacol 1998, 361:1-15.
16. Hieble JP, Bylund DB, Clarke DE, et al. International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev 1995, 47:267-270.
17. Zimmer HG Otto Loewi and the chemical transmission of vagus stimulation in the heart. Clin Cardiol 2006, 3:135-136.
18. Dixon RA, Kobilka BK, Strader DJ, et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 1986, 321:75-79.
19. Royster RL Intraoperative administation of inotropes in cardiac surgery patients. J Cardiothor Anesth 1990, 4:17S-28S.
20. Berkowitz DE, Schwinn DA Basic pharmacology of alpha and beta adrenoceptors 1994, 581-605. Churchill Livingstone, New York. T.A. Bowdle, A. Horita, E.D. Kharasch (Eds.).
21. Rasmussen SG, DeVree BT, Zou Y, et al. Crystal structure of the β(2) adrenergic receptor-Gs protein complex. Nature 2011, 477(7366):549-555.
22. Hawrylyshyn KA, Michelotti GA, Coge F, Guenin SP, Schwinn DA Update on human alpha1-adrenoceptor subtype signaling and genomic organization. Trends Pharmacol Sci 2004, 25:449-455.
23. Undieh AS Pharmacology of signaling induced by dopamine D(1)-like receptor activation. Pharmacol Ther 2010, 128:37-60.
24. Bylund DB Heterogeneity of alpha-2 adrenergic receptors. Pharmacol Biochem Behav 1985, 22:835-843.
25. Khan ZP, Ferguson CN, Jones RM Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia 1999, 54:146-165.
26. Kaumann AJ, Lemoine H Beta 2-adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation. Naunyn Schmiedebergs Arch Pharmacol 1987, 335:403-411.
27. Lipworth BJ Clinical pharmacology of beta 3-adrenoceptors. Br J Clin Pharmacol 1996, 42:291-300.
28. Friedrich JO, Adhikari N, Herridge MS, Beyene J Metaanalysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005, 142:510-524.
29. Goldberg LI Dopamine receptors and hypertension. Physiologic and pharmacologic implications. Am J Med 1984, 77:37-44.
30. Halpenny M, Lakshmi S, O'Donnell A, O'Callaghan-Enright S, Shorten GD Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 2001, 56:953-960.
31. Gilbert TB, Hasnain JU, Flinn WR, Lilly MP, Benjamin ME Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair. J Cardiovasc Pharmacol Ther 2001, 6:31-36.
32. Brienza N, Malcangi V, Dalfino L, et al. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Crit Care Med 2006, 34:707-714.
33. Landoni G, Biondi-Zoccai GG, Marino G, et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2008, 22:27-33.
34. Thiele RH, Nemergut EC, Lynch C The physiologic implications of isolated alpha1 adrenergic stimulation. Anesth Analg 2011, 113:284-296.
35. Lorhan PH, Oliverio RM A study of the use of neosynephrine hydrochloride in spinal anesthesia in place of ephedrine for the sustaining of blood pressure. Curr Res Anesth Analg 1938, 17:44.
36. Erkinaro T, Kavasmaa T, Pakkila M, et al. Ephedrine and phenylephrine for the treatment of maternal hypotension in a chronic sheep model of increased placental vascular resistance. Br J Anaesth 2006, 96:231-237.
37. Erkinaro T, Makikallio K, Kavasmaa T, Alahuhta S, Rasanen J Effects of ephedrine and phenylephrine on uterine and placental circulations and fetal outcome following fetal hypoxaemia and epidural-induced hypotension in a sheep model. Br J Anaesth 2004, 93:825-832.
38. Groudine SB, Hollinger I, Jones J, DeBouno BA New York State guidelines on the topical use of phenylephrine in the operating room: the Phenylephrine Advisory Committee. Anesthesiology 2000, 92:859-864.
39. King BD, Dripps RD Use of methoxamine for maintenance of the circulation during spinal anesthesia. Surg Gynec Obstet 1950, 90:659.
40. Lakhlani PP, MacMillan LB, Guo TZ, et al. Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci U S A 1997, 94:9950-9955.
41. Hunter JC, Fontana DJ, Hedley LR, et al. Assessment of the role of alpha2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol 1997, 122:1339-1344.
42. Ma D, Hossain M, Rajakumaraswamy N, et al. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 2004, 502:87-97.
43. Ebert T, Maze M Dexmedetomidine: another arrow for the clinician's quiver. Anesthesiology 2004, 101:568-570.
44. Wijeysundera DN, Naik JS, Beattie WS Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med 2003, 114:742-752.
45. Stevens JE Rebound hypertension during anaesthesia. Anaesthesia 1980, 35:490-491.
46. Aantaa R, Jalonen J Perioperative use of alpha2-adrenoceptor agonists and the cardiac patient. Eur J Anaesthesiol 2006, 23:361-372.
47. Arain SR, Ruehlow RM, Uhrich TD, Ebert TJ Efficacy of dexmedetomidine versus morphine for post-operative analgesia following major inpatient surgery. Anesth Analg 2004, 98:153-158.
48. Herr DL, Sum-Ping ST, England M ICU sedation after coronary artery bypass graft surgery: dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothorac Vasc Anesth 2003, 17:576-584.
49. Riker RR, Shehabi Y, Bokesch PM, et al. SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group: Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009, 301:489-499.
50. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007, 298:2644-2653.
51. Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY Monitored anesthesia care with dexmedetomidine. Anesth Analg 2010, 110:47-56.
52. Retrieved July 18. http://Drugs.com/ppa/isoproterenol.html.
53. Butterworth JF, Royster RL, Prielipp RC, Lawless ST, Wallenhaupt SL Amrinone in cardiac surgical patients with left-ventricular dysfunction. A prospective, randomized placebo-controlled trial. Chest 1993, 104:1660-1667.
54. Fowler MB, Alderman EL, Oesterle SN, et al. Dobutamine and dopamine after cardiac surgery: greater augmentation of myocardial blood flow with dobutamine. Circulation 1984, 70:I103-I111.
55. Braden GL, Germain MJ, Mulhern JG, Hafer JG, Bria WF Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline in asthmatic patients. Chest 1998, 114:380-387.
56. Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N Engl J Med 1992, 327:308-312. The Canadian Preterm Labor Investigators Group.
57. Biaggioni I, Robertson D Chapter 9. Adrenoceptor agonists and sympathomimetic drugs. Basic and Clinical Pharmacology 2011, McGraw-Hill, New York. 11th ed. B.G. Katzung, S.B. Masters, A.J. Trevor (Eds.).
58. Gillman PK Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005, 95:434-441.
59. Barash PG, Cullen BF, Stoelting RK, Cahalan MK, Stock MC Clinical Anesthesia 2009, Lippincott Williams and Wilkins, Philadelphia, 358. 6th ed.
60. Huyse FJ, Touw DJ, Strack van Schijndel R, deLange JJ, Slaets JP Psychotropic drugs and the perioperative period: a proposal guide for elective surgery. Psychosomatics 2006, 47:8-22.
61. Chadha NK, Repanos C, Carswell AJ Local anesthesia for manipulation of nasal fractures: systematic review. J Laryngol Otol 2009, 123:830-836.
62. Mitra JK, Roy J, Sengupta S Vasopressin: its current role in anesthetic practice. Ind J Crit Care Med 2011, 15:71-77.
63. Dunser MW, Mayr AJ, Ulmet H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003, 107:2313-2319.
64. Raab H, Lindner KH, Wenzel V Preventing cardiac arrest during hemorrhagic shock with vasopressin. Crit Care Med 2008, 36(Suppl):S474-S480.
65. Stadlbauer KH, Wenzel V, Krismer AC, Voelckel WG, Lindner KH Vasopressin during uncontrolled hemorrhagic shock: less bleeding below the diaphragm, more perfusion above. Anesth Analg 2005, 101:830-832.
66. Tsuneyoshi I, Onomoto M, Yonetani A, Kanmura Y Low-dose vasopressin infusion in patients with severe vasodilatory hypotension after prolonged hemorrhage during general anesthesia. J Anesth 2005, 19:170-173.
67. Sharma RM, Setlur R Vasopressin in hemorrhagic shock. Anesth Analg 2005, 101:833-834.
68. Kertai MD, Bax JJ, Klein J, Poldermans D Is there any reason to withhold beta blockers from high-risk patients with coronary artery disease during surgery?. Anesthesiology 2004, 100:4-7.
69. Silverman NA, Wright R, Levitsky S Efficacy of low-dose propranolol in preventing postoperative supraventricular tachyarrhythmias: a prospective, randomized study. Ann Surg 1982, 196:194-197.
70. Giles JW, Sear JW, Foex P Effect of chronic beta-blockade on perioperative outcome in patients undergoing non-cardiac surgery: an analysis of observational and case control studies. Anaesthesia 2004, 59:574-583.
71. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999, 341:1789-1794.
72. Mangano DT, Layug EL, Wallace A, Tateo I Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 1996, 335:1713-1720.
73. Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008, 371:1839-1847. POISE Study Group.
74. Egstrup K Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. Am J Cardiol 1988, 61:1219-1222.
75. Gorczynski RJ Basic pharmacology of esmolol. Am J Cardiol 1985, 56:3F-13F.
76. Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, Lai CM Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther 1983, 34:427-434.
77. MacCarthy EP, Bloomfield SS Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy 1983, 3:193-219.
78. Wallace AW, Au S, Cason BA Perioperative beta-blockade: atenolol is associated with reduced mortality when compared to metoprolol. Anesthesiology 2011, 114:824-836.
79. Brown DA Muscarinic acetylcholine receptors (mAChRs) in the nervous system: some functions and mechanisms. J Mol Neurosci 2010, 41:340-346.
80. Caulfield MP Muscarinic receptors-characterization, coupling and function. Pharmacol Ther 1993, 58:319-379.
81. Barash PG, Cullen BF, Stoelting RK, Cahalan MK, Stock MC Clinical Anesthesia 2009, Lippincott Williams and Wilkins, Philadelphia, 502. 6th ed.
82. Raczkowska M, Ebert TJ, Eckberg DL Muscarinic cholinergic receptors modulate vagal cardiac responses in man. J Autonomic Nerv Syst 1983, 7:271-278.
83. Ali-Melkkila T, Kanto J, Iisalo E Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 1993, 37:633-642.
84. Apfel CC, Zhang K, George E, et al. Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis. Clin Ther 2010, 32:1987-2002.
85. Renner UD, Oertel R, Kirch W Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit 2005, 27:655-665.
86. Flynn RA, Glynn DA, Kennedy MP Anticholinergic treatment in airways diseases. Adv Ther 2009, 26:908-919.
87. Gross NJ Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006, 533:36-39.